NovaBay Pharmaceuticals, Inc.  

(Public, NYSEMKT:NBY)   Watch this stock  
Find more results for NBY
0.630
+0.012 (2.01%)
Jan 27 - Close
NYSEMKT real-time data - Disclaimer
Currency in USD
Range 0.62 - 0.65
52 week 0.53 - 1.38
Open 0.63
Vol / Avg. 101,298.00/160,295.00
Mkt cap 32.40M
P/E     -
Div/yield     -
EPS -0.32
Shares 51.63M
Beta 0.59
Inst. own 6%
Mar 30, 2015
Q4 2014 NovaBay Pharmaceuticals Inc Earnings Release (Estimated) Add to calendar
Feb 10, 2015
NovaBay Pharmaceuticals Inc at Biotechnology Industry Organization CEO & Investor Conference - 1:00PM EST - Add to calendar
Nov 12, 2014
Q3 2014 NovaBay Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -2775.66% -461.37%
Operating margin -2705.92% -445.38%
EBITD margin - -436.35%
Return on average assets -137.83% -91.97%
Return on average equity -226.99% -142.18%
Employees 29 -
CDP Score - -

Address

Suite 550, 5980 Horton Street
EMERYVILLE, CA 94608
United States - Map
+1-510-8998800 (Phone)
+1-510-2250371 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

NovaBay Pharmaceuticals, Inc. (NovaBay) is a clinical-stage biotechnology company focused on addressing the unmet therapeutic needs of the global anti-infective market. The Company�s Aganocide compounds, led by NVC-422, are patented, synthetic molecules with a spectrum of activity against bacteria, viruses and fungi. The Company focuses on the following therapeutic markets: Dermatology, Ophthalmology and Urology. The Company�s irrigation solution containing NVC-422 is in Phase II clinical studies, with the goal of reducing the incidence of urinary catheter blockage and encrustation (UCBE) and the associated urinary tract infections. The Company is also developing another class of molecule, NeutroPhase, which is an FDA 510(k)-cleared product for advanced wound care.

Officers and directors

Ramin Najafi Ph.D. Chairman of the Board, President, Chief Executive Officer
Age: 55
Bio & Compensation  - Reuters
Thomas J. Paulson Chief Financial Officer, Treasurer, Secretary
Age: 67
Bio & Compensation  - Reuters
Keith R. Bley Ph.D. Senior Vice President - Product Development
Age: 54
Bio & Compensation  - Reuters
David W. Stroman Ph.D. Senior Vice President - Ophthalmic Product Development
Age: 69
Bio & Compensation  - Reuters
Roy J. Wu Senior Vice President - Business & Corporate Development
Age: 59
Bio & Compensation  - Reuters
T. Alexander McPherson M.D., Ph.D. Lead Independent Director
Age: 75
Bio & Compensation  - Reuters
Massimo Radaelli Ph.D. Director
Age: 56
Bio & Compensation  - Reuters
Mark M. Sieczkarek Director
Age: 59
Bio & Compensation  - Reuters
Charles J. Cashion Independent Director
Age: 63
Bio & Compensation  - Reuters
Paul E. Freiman Independent Director
Age: 79
Bio & Compensation  - Reuters